1.2.2005: Meldung: Spire Corporation: NSF Grant to Develop Blood-Compatible Catheters
Monday January 31, 10:19 am ET
BEDFORD, Mass.-- Jan. 31, 2005--Spire Corporation (Nasdaq: SPIR - News):
* Nano-engineered biological coatings designed to prevent blood clotting.
* Biological coatings aimed at enhancing Spire"s hemodialysis product line.
Spire Corporation (Nasdaq: SPIR - News) today announced the receipt of a two-year SBIR Phase II grant of $498,764 from the National Science Foundation ("NSF") to continue the development of blood-compatible dialysis catheters, used for the treatment of end-stage renal disease ("ESRD") dialysis patients.
Under Phase I of the program, Spire demonstrated through in-vitro studies that its proprietary surface treatment reduces the potential for catheter related thrombosis. This treatment results in a nano-engineered biological coating that combines protein passivation, anticoagulation, and fibriolytic chemistry that is integrated onto an atomically nano-textured surface.
Mark Little, CEO of Spire Biomedical, stated, "Vascular access complications cost our healthcare system more than $2 billion annually. Clotting of catheters reduces vascular access potency, requiring intervention and disrupting treatment. Domestically, industry experts estimate that nearly 600,000 hemodialysis catheters alone are sold each year with a market value of more than $100 million. Applying this new technology to dialysis catheters will provide major benefits for physicians, hospital staff, and most importantly, the patients."
Spire Biomedical offers a full line of chronic hemodialysis catheters. The Company is also a leading provider of surface engineering technology for biomedical devices.
Spire Corporation is a diversified technology company serving the biomedical, solar energy, telecommunications and defense industries worldwide with innovative products and services based upon a common technology platform.
Roger G. Little
Source: Spire Corporation